Development of innovative paclitaxel-loaded small PLGA nanoparticles: Study of their antiproliferative activity and their molecular interactions on prostatic cancer cells

International Journal of Pharmaceutics

Volumn 454, Issue 2, 2013, Pages 712-719

  Le Broc Ryckewaert, D ^a,b   Carpentier, R ^a,c   Lipka, E ^a   Daher, S ^a,b   Vaccher, C ^a   Betbeder, D ^a,c,d   Furman, C ^a,b,e  

^a UNIV LILLE   (France)

^b UFR3S Pharmacie   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ D'ARTOIS   (France)

^e Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Chemoresistance; Paclitaxel; Prostate cancer; Small PLGA nanoparticles

Indexed keywords

NANOPARTICLE; PACLITAXEL; POLYGLACTIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENDOCYTOSIS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE CHARGE; ZETA POTENTIAL;

1,1′-DIOCTADECYL-3,3,3′,3′-TETRAMETHYLINDOCARBOCYANINE PERCHLORATE; 3-[4,5-DIMETHYLTHIAZOL-2-YL]-2,5 DIPHENYLTETRAZOLIUM BROMIDE; BCA; BICINCHONINIC ACID; BOVINE SERUM ALBUMIN; BSA; CHEMORESISTANCE; CTAB; DII; EP; FBS; FOETAL BOVINE SERUM; HEXADECYLTRIMETHYLAMMONIUM BROMIDE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; MTT; NANOPARTICLES; NP; P-GLYCOPROTEIN; P-GP; PACLITAXEL; PBS; PDI; PHENYLMETHANESULFONYLFLUORIDE; PHOSPHATE BUFFER SALINE; PLGA; PMSF; POLY(LACTIC-CO-GLYCOLIC) ACID; POLYDISPERSITY INDEX; PROSTATE CANCER; PTX; R EFFECTENHANCED AND PERMEABILITY RETENTION EFFECT; SDS; SMALL-PLGA NANOPARTICLES; SODIUM DODECYL SULFATE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOCYTOSIS; HUMANS; LACTIC ACID; MALE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYGLYCOLIC ACID; PROSTATIC NEOPLASMS; SURFACE PROPERTIES;

EID: 84884163967     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.05.018     Document Type: Article

References (65)

1. Abdelwahed, W., Degobert, G., Fessi, H., 2006. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int. J. Pharm. 309, 178-188. (Pubitemid 43129481)
2. AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer. Registries), 2008.
3. Akaza, H., Homma, Y., Usami, M., Hirao, Y., Tsushima, T., Okada, K., Yokoyama, M., Ohashi, Y., Aso, Y., 2006. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. Prostate Cancer Study Group. B.J.U. Int. 98, 573-579. (Pubitemid 44185879)
4. Alyautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kharkevich, D.A., Kreuter, J., 1997. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14, 325-328. (Pubitemid 27160944)
5. Antonarakis, E.S., Blackford, A.L., Garrett-Mayer, E., Eisenberger, M.A., 2007. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J. Clin. Oncol. 25, 4998-5008. (Pubitemid 350220434)
6. Bhangal, G., Halford, S., Wang, J., Roylance, R., Shah, R., Waxman, J., 2000. Expression of the multidrug resistance gene in human prostate cancer. Urol. Oncol. 5, 118-121. (Pubitemid 30182540)
7. Chang, J., Jallouli, Y., Kroubi, M., Yuan, X.B., Feng, W., Kang, C.S., Pu, P.Y., Betbeder, D., 2009. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm. 379, 285-292.
8. Chang, J., Paillard, A., Passirani, C., Morille, M., Benoit, J.P., Betbeder, D., Garcion, E., 2012. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. 29, 1495-1505.
9. Cho, H.S., Dong, Z., Pauletti, G.M., Zhang, J., Xu, H., Gu, H., Wang, L., Ewing, R.C., Huth, C., Wang, F., Shi, D., 2010. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 4, 5398-5404.
10. Chung, Y.I., Kim, J.C., Kim, Y.H., Tae, G., Lee, S.Y., Kim, K., Kwon, I.C., 2010. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated pluronic on tumor targeting. J. Control Release 143, 374-382.
11. Danhier, F., Lecouturier, N., Vroman, B., Jérôme, C., Marchand-Brynaert, J., Feron, O., Préat, V., 2009. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control Release 133, 11-17.
12. Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Le Breton, A., Préat, V., 2012. PLGA-based nanoparticles: an overview of biomedical applications. J. Control Release 161, 505-522.
13. Dinarvand, R., Sepehri, N., Manoochehri, S., Rouhani, H., Atyabi, F., 2011. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int. J. Nanomed. 6, 877-895.
14. English, D.P., Roque, D.M., Santin, A.D., 2013. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Rev. Anticancer Ther. 13, 63-74.
15. Farokhzad, O.C., Cheng, J., Teply, B.A., Sheri., I., Jon, S., Kantoff, P.W., Richie, J.P., Langer, R., 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 6315-6320.
16. Fizazi, K., Navone, N.M., 2005. Preclinical models of prostate cancer. Bull. Cancer 92, 129-141. (Pubitemid 40396120)
17. Fonseca, C., Simões, S., Gaspar, R., 2002. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control Release 83, 273-286.
18. Gaumet, M., Vargas, A., Gurny, R., Delie, F., 2008. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 69, 1-9. (Pubitemid 351467152)
19. Gelderblom, H., Verweij, J., Nooter, K., Sparreboom, A., 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598. (Pubitemid 32778603)
20. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., O'Shaughnessy, J., 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803. (Pubitemid 46657376)
21. Gronberg, H., 2003. Prostate cancer epidemiology. Lancet 361, 859-864. (Pubitemid 36331852)
22. Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D.B., Nettles, J.H., Snyder, J.P., Greenberger, L.M., 2006. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5, 270-278.
23. Haley, B., Frenkel, E., 2008. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26, 57-64.
24. Hawkins, M.J., Soon-Shiong, P., Desai, N., 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60, 876-885.
25. Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., Esmaeli, B., Ring, S.E., Bedikian, A., Hortobagyi, G.N., Ellerhorst, J.A., 2002. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044. (Pubitemid 34517637)
26. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., 2009. Cancer statistics, 2009. Cancer J. Clin. 59, 225-249.
27. Jordan, M.A., Wilson, L., 2004. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265. (Pubitemid 38525281)
28. Kaighn, M.E., Narayan, K.S., Ohnuki, Y., Lechner, J.F., Jones, L.W., 1979. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17, 16-23. (Pubitemid 9239413)
29. Kim, J.J., Yin, B., Christudass, C.S., Terada, N., Rajagopalan, K., Fabry, B., Lee, D.Y., Shiraishi, T., Getzenberg, R.H., Veltri, R.W., An, S.S., Mooney, S.M., 2013. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J. Cell Biochem. 114 (6), 1286-1293.
30. Krishna, R., Mayer, L.D., 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283.
31. Li, J., Djenaba, J.A., Soman, A., Rim, S.H., Master, V.A., 2012. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer, http://dx.doi.org/10.1155/2012/691380 [Epub ahead of print].
32. Links, M., Brown, R., 1999. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med. 1999, 1-21.
33. Lu, J., Jackson, J.K., Gleave, M.E., Burt, H.M., 2008. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother. Pharmacol. 61, 997-1005. (Pubitemid 351423128)
34. Madan, R.A., Pal, S.K., Sartor, O., Dahut, W.L., 2011. Overcoming chemotherapy resistance in prostate cancer. Clin. Cancer Res. 17, 3892-3902.
35. Mancuso, A., Oudard, S., Sternberg, C.N., 2007. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit. Rev. Oncol. Hematol. 61, 176-185. (Pubitemid 46091748)
36. Matsumura, Y., Maeda, H., 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392. (Pubitemid 17221789)
37. Mu, L., Feng, S.S., 2003. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control Release 86, 33-48. (Pubitemid 35469120)
38. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., 2008. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control Release 125, 193-209.
39. Nyman, D.W., Campbell, K.J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M.J., Von Hoff, D.D., 2005. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23, 7785-7793. (Pubitemid 46657375)
40. Olivier, J.C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., Couet, W., 1999. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16, 1836-1842. (Pubitemid 30040699)
41. Olivier, J.C., 2005. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119.
42. Panyam, J., Labhasetwar, V., 2003. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 20, 212-220. (Pubitemid 36277684)
43. Petrylak, D.P., Tangen, C.M., Hussain, M.H., Lara Jr., P.N., Jones, J.A., Taplin, M.E., Burch, P.A., Berry, D., Moinpour, C., Kohli, M., Benson, M.C., Small, E.J., Raghavan, D., Crawford, E.D., 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520. (Pubitemid 39315318)
44. Qaddoumi, M.G., Gukasyan, H.J., Davda, J., Labhasetwar, V., Kim, K.J., Lee, V.H., 2003. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol. Vis. 9, 559-568. (Pubitemid 38097623)
45. Rowinsky, E.K., Donehower, R.C., 1995. Paclitaxel (taxol). N. Engl. J. Med. 332, 1004-1014.
46. Sahoo, S.K., Ma, W., Labhasetwar, V., 2004. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112, 335-340. (Pubitemid 39244375)
47. Sanna, V., Roggio, A.M., Posadino, A.M., Cossu, A., Marceddu, S., Mariani, A., Alzari, V., Uzzau, S., Pintus, G., Sechi, M., 2011. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res. Lett. 6, 260-269.
48. Sartor, O., Bruland, O., 2011. Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge. Clin. Genitourin. Cancer 9, 1-2.
49. Shah, N., Chaudhari, K., Dantuluri, P., Murthy, R.S., Das, S., 2009. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J. Drug Target. 17, 533-542.
50. Shapira, A., Livney, Y.D., Broxterman, H.J., Assaraf, Y.G., 2011. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug. Resist. Updat. 14, 150-163.
51. Socinski, M., 2006. Update on nanoparticle albumin-bound paclitaxel. Clin. Adv. Hematol. Oncol. 4, 745-746. (Pubitemid 44794704)
52. Surapaneni, M.S., Das, S.K., Das, N.G., 2012. Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol. 2012, http://dx.doi.org/10.5402/2012/623139, Article ID 623139.
53. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Théodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A., 2004. TAX 327 investigators, docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512. (Pubitemid 39315317)
54. Tarr, B.D., Yalkowsky, S.H., 1987. A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J. Parenter. Sci. Technol. 41, 31-33. (Pubitemid 17034075)
55. Thadani-Mulero, M., Nanus, D.M., Giannakakou, P., 2012. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 72, 4611-4615.
56. Tulpule, A., Groopman, J., Saville, M.W., Harrington Jr., W., Friedman-Kien, A., Espina, B.M., Garces, C., Mantelle, L., Mettinger, K., Scadden, D.T., Gill, P.S., 2002. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95, 147-154. (Pubitemid 34743493)
57. Van Amersfoort, E.S., Van Strijp, J.A.G., 1994. Evaluation of a flow cytometric fluorescence quenching assay of phagocytosis of sensitized sheep erythrocytes by polymorphonuclear leukocytes. Cytometry 17, 294-301.
58. Van Brussel, J.P., Jan Van Steenbrugge, G., Van Krimpen, C., Bogdanowicz, J.F., Van Der Kwast, T.H., Schröder, F.H., Mickisch, G.H., 2001. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J. Urol. 165, 130-135.
59. Van Brussel, J.P., Mickisch, G.H., 2003. Multidrug resistance in prostate cancer. Onkologie 26, 175-181. (Pubitemid 36677083)
60. Vicari, L., Musumeci, T., Giannone, I., Adamo, L., Conticello, C., De Maria, R., Pignatello, R., Puglisi, G., Gulisano, M., 2008. Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. B.M.C. Cancer 8, 212-223.
61. Weissenböck, A., Wirth, M., Gabor, F., 2004. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J. Control Release 99, 383-392. (Pubitemid 39296907)
62. Win, K.Y., Feng, S.S., 2006. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713-2722.
63. Xie, J., Wang, C.H., 2005. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm. Res. 22, 2079-2090. (Pubitemid 41821587)
64. Yared, J.A., Tkaczuk, K.H., 2012. Update on taxane development: new analogs and new formulations. Drug Des. Devel. Ther. 6, 371-384.
65. Zhao, P., Astruc, D., 2012. Docetaxel nanotechnology in anticancer therapy. Chem. Med. Chem. 7, 952-972.